Corinna Modiz, Natalia M Castoldi, Stefan Scheiner, Javier Martínez-Reina, Jose L Calvo-Gallego, Vittorio Sansalone, Saulo Martelli, Peter Pivonka
{"title":"Computational simulations of endocrine bone diseases related to pathological glandular PTH secretion using a multi-scale bone cell population model.","authors":"Corinna Modiz, Natalia M Castoldi, Stefan Scheiner, Javier Martínez-Reina, Jose L Calvo-Gallego, Vittorio Sansalone, Saulo Martelli, Peter Pivonka","doi":"10.3389/fbioe.2025.1619276","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Bone diseases significantly impact global health by compromising skeletal integrity and quality of life. In disease states linked to parathyroid hormone (PTH) glandular secretion, disrupted PTH patterns typically promote osteoclast proliferation, leading to increased bone resorption.</p><p><strong>Methods: </strong>While mathematical modeling has proven valuable in analyzing bone remodeling, current bone cell population models oversimplify PTH secretion by assuming constant levels, limiting their ability to represent disorders characterized by variations in PTH pulse characteristics. To address this, we present a novel semi-coupled approach integrating a two-state PTH receptor model with an established bone cell population model. Instead of conventional Hill-type functions, we implement a cellular activity function derived from the receptor model, incorporating pulsatile PTH patterns, cell dynamics, and intracellular communication pathways.</p><p><strong>Results: </strong>Our numerical simulations demonstrate the model's capability to reproduce various catabolic bone diseases, providing realistic changes in bone volume fraction over a 1-year period. Notably, while direct implementation of PTH disease progression in the bone cell population model fails to capture diseases only characterized by altered pulse duration and baseline, such as glucocorticoid-induced osteoporosis, our semi-coupled approach successfully models these conditions.</p><p><strong>Discussion: </strong>This physiologically more realistic approach to endocrine disease modeling offers potential implications for optimizing therapeutic interventions and understanding disease progression mechanisms.</p>","PeriodicalId":12444,"journal":{"name":"Frontiers in Bioengineering and Biotechnology","volume":"13 ","pages":"1619276"},"PeriodicalIF":4.8000,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12521151/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers in Bioengineering and Biotechnology","FirstCategoryId":"5","ListUrlMain":"https://doi.org/10.3389/fbioe.2025.1619276","RegionNum":3,"RegionCategory":"工程技术","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"BIOTECHNOLOGY & APPLIED MICROBIOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Introduction: Bone diseases significantly impact global health by compromising skeletal integrity and quality of life. In disease states linked to parathyroid hormone (PTH) glandular secretion, disrupted PTH patterns typically promote osteoclast proliferation, leading to increased bone resorption.
Methods: While mathematical modeling has proven valuable in analyzing bone remodeling, current bone cell population models oversimplify PTH secretion by assuming constant levels, limiting their ability to represent disorders characterized by variations in PTH pulse characteristics. To address this, we present a novel semi-coupled approach integrating a two-state PTH receptor model with an established bone cell population model. Instead of conventional Hill-type functions, we implement a cellular activity function derived from the receptor model, incorporating pulsatile PTH patterns, cell dynamics, and intracellular communication pathways.
Results: Our numerical simulations demonstrate the model's capability to reproduce various catabolic bone diseases, providing realistic changes in bone volume fraction over a 1-year period. Notably, while direct implementation of PTH disease progression in the bone cell population model fails to capture diseases only characterized by altered pulse duration and baseline, such as glucocorticoid-induced osteoporosis, our semi-coupled approach successfully models these conditions.
Discussion: This physiologically more realistic approach to endocrine disease modeling offers potential implications for optimizing therapeutic interventions and understanding disease progression mechanisms.
期刊介绍:
The translation of new discoveries in medicine to clinical routine has never been easy. During the second half of the last century, thanks to the progress in chemistry, biochemistry and pharmacology, we have seen the development and the application of a large number of drugs and devices aimed at the treatment of symptoms, blocking unwanted pathways and, in the case of infectious diseases, fighting the micro-organisms responsible. However, we are facing, today, a dramatic change in the therapeutic approach to pathologies and diseases. Indeed, the challenge of the present and the next decade is to fully restore the physiological status of the diseased organism and to completely regenerate tissue and organs when they are so seriously affected that treatments cannot be limited to the repression of symptoms or to the repair of damage. This is being made possible thanks to the major developments made in basic cell and molecular biology, including stem cell science, growth factor delivery, gene isolation and transfection, the advances in bioengineering and nanotechnology, including development of new biomaterials, biofabrication technologies and use of bioreactors, and the big improvements in diagnostic tools and imaging of cells, tissues and organs.
In today`s world, an enhancement of communication between multidisciplinary experts, together with the promotion of joint projects and close collaborations among scientists, engineers, industry people, regulatory agencies and physicians are absolute requirements for the success of any attempt to develop and clinically apply a new biological therapy or an innovative device involving the collective use of biomaterials, cells and/or bioactive molecules. “Frontiers in Bioengineering and Biotechnology” aspires to be a forum for all people involved in the process by bridging the gap too often existing between a discovery in the basic sciences and its clinical application.